Tregs and allergic disease.
Tregs and allergic disease.
复制标题
DOI：
10.1172/jci23595
复制
发表时间：
2004-11
期刊：
影响因子：
--
通讯作者：
D. Robinson;M. Larché;S. Durham
中科院分区：
文献类型：
--
作者：
D. Robinson;M. Larché;S. Durham
过敏性疾病，如哮喘，鼻炎和湿疹的患病率正在增加，并影响到西方国家高达15%的人口。将Tcells描述为防止自身免疫性疾病发展的T细胞，引起了人们对这些Tcells是否也正常参与预防对过敏原的致敏以及是否可能操纵Tcells用于治疗过敏性疾病的兴趣。目前的数据表明，对过敏原的Th 2应答通常被CD 4 + CD 25 + T细胞亚群和IL-10 T细胞亚群抑制。此外，这些亚群的抑制在过敏性个体中减少。在动物模型中，高剂量或低剂量的吸入抗原可诱导TclO，并且在吸入激发模型中，预先诱导这种TclO可防止随后过敏原致敏和气道炎症的发展。多年来，过敏原注射免疫疗法已用于治疗过敏性疾病，并且该治疗可诱导IL-10 T细胞活化，从而导致Th 2应答的抑制和从IgE到IgG 4抗体产生的转换。过敏原免疫疗法的改进，如肽疗法，以及对过敏原生物学的更深入了解，为治疗和预防过敏性疾病带来了巨大希望。
Allergic diseases such as asthma, rhinitis, and eczema are increasing in prevalence and affect up to 15% of populations in Westernized countries. The description of Tregs as T cells that prevent development of autoimmune disease led to considerable interest in whether these Tregs were also normally involved in prevention of sensitization to allergens and whether it might be possible to manipulate Tregs for the therapy of allergic disease. Current data suggest that Th2 responses to allergens are normally suppressed by both CD4+CD25+ Tregs and IL-10 Tregs. Furthermore, suppression by these subsets is decreased in allergic individuals. In animal models, Tregs could be induced by high- or low-dose inhaled antigen, and prior induction of such Tregs prevented subsequent development of allergen sensitization and airway inflammation in inhaled challenge models. For many years, allergen-injection immunotherapy has been used for the therapy of allergic disease, and this treatment may induce IL-10 Tregs, leading to both suppression of Th2 responses and a switch from IgE to IgG4 antibody production. Improvements in allergen immunotherapy, such as peptide therapy, and greater understanding of the biology of Tregs hold great promise for the treatment and prevention of allergic disease.